Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.61 |
| ▸ | GRM5 | P41594 | 7/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | OGT | O15294 | 1/20 | 0.48 |
| ▸ | KMO | O15229 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 2/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30146353 | 1.00 | PSMB8 (0.61) | PSMB8GRM5MCL1OGTKMO | |
| SCHEMBL22981043 | 0.84 | PSMB8 (0.46) | PSMB8GRM5MCL1OGTKMO | |
| SCHEMBL1904323 | 0.77 | F2 (0.52) | PSMB8MCL1CA12CA9LMNA | |
| SCHEMBL5540274 | 0.76 | MCL1 (0.49) | GRM5MCL1OGTEPHX2NOS1 | |
| SCHEMBL31686101 | 0.76 | MCL1 (0.49) | GRM5MCL1OGTEPHX2 | |
| SCHEMBL2484702 | 0.76 | MCL1 (0.49) | GRM5MCL1OGTEPHX2 | |
| SCHEMBL1285749 | 0.76 | EPHX2 (0.50) | GRM5MCL1OGTEPHX2NOS3 | |
| SCHEMBL1137634 | 0.76 | PSMB8 (0.61) | PSMB8GRM5MCL1OGTEPHX2 | |
| SCHEMBL3043379 | 0.76 | MCL1 (0.49) | GRM5MCL1OGTCA12CA9 | |
| SCHEMBL3306201 | 0.76 | MCL1 (0.49) | PSMB8GRM5MCL1OGTKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289753-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-09-15 | — | — | US | disclosed |
| CN-114728935-A | SHP2 inhibitor | IRBM股份公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4010335-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021028362-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2021-02-18 | — | — | WO | disclosed |
| CN-106866801-A | Tuberculosis RV2386C albumen, composition and application thereof | 葛兰素史密丝克莱恩生物有限公司 | 2017-06-20 | — | — | CN | disclosed |
| CN-102165064-B | Tuberculosis RV2386C protein, composition and application thereof | 葛兰素史密丝克莱恩生物有限公司 | 2017-06-20 | — | — | CN | disclosed |
| CN-105018506-A | Hydrolase of benzoxazolone compound, gene for coding hydrolase and engineering strain containing gene and application thereof | UNIV NANJING AGRICULTURAL | 2015-11-04 | — | — | CN | disclosed |
| EP-1381598-A4 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-03-19 | — | — | EP | disclosed |
| US-7223757-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7081454-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2006-07-25 | — | — | US | disclosed |
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-04 | — | — | US | disclosed |
| EP-1381598-A1 | NOVEL TYROSINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-01-21 | — | — | EP | disclosed |
| EP-1263427-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-12-11 | — | — | EP | disclosed |
| WO-2002079192-A1 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2001068084-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-20 | — | — | WO | disclosed |
| EP-1085820-A1 | SOY HYDROLYSATE AND USE IN INSECT CONTROL | Tuzun, Sadik (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999063840-A1 | SOY HYDROLYSATE AND USE IN INSECT CONTROL | TUZUN SADIK (US) | 1999-12-16 | — | — | WO | disclosed |
| US-4716204-A | ADDUCTS OF BENZO-N-HETEROCYCLES | THE DOW CHEMICAL COMPANY (US) | 1987-12-29 | — | — | US | disclosed |
| US-4631331-A | BENZO-N-HETEROCYCLES | THE DOW CHEMICAL COMPANY (US) | 1986-12-23 | — | — | US | disclosed |
| EP-0014263-A2 | Method of improving the solubility of biologically active agents in water and in lower aliphatic alcohols, and compounds having an improved solubility | BAYER AG (DE) | 1980-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289753-A1 | SHP2 INHIBITORS | PTPN1, PTPN2, PTPN7 | PSMB8 1657/4885GRM5 1734/4885MCL1 184/4885 |
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | ABL1, YES1, FER | PSMB8 3972/4885GRM5 3736/4885MCL1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.